Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 3/20 | 0.76 |
| ▸ | MEN1 | O00255 | 4/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.65 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 6/20 | 0.59 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.58 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.51 |
| ▸ | RORC | P51449 | 2/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.50 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15101483 | 1.00 | MCL1 (0.76) | MCL1MEN1KMT2ABCL2L1MAPT | |
| SCHEMBL30076604 | 0.88 | MCL1 (0.86) | MCL1MEN1KMT2ABCL2L1MAPT | |
| SCHEMBL15101435 | 0.88 | MCL1 (0.86) | MCL1MEN1KMT2ABCL2L1MAPT | |
| SCHEMBL15101448 | 0.88 | MCL1 (0.76) | MCL1MEN1KMT2ABCL2L1MAPT | |
| SCHEMBL15101434 | 0.88 | MCL1 (0.76) | MCL1MEN1KMT2ABCL2L1MAPT | |
| SCHEMBL18392354 | 0.88 | MCL1 (0.76) | MCL1MEN1KMT2ABCL2L1MAPT | |
| SCHEMBL18392356 | 0.86 | MCL1 (1.00) | MCL1MEN1KMT2ABCL2L1MAPT | |
| SCHEMBL1494846 | 0.85 | MAPT (0.57) | MCL1MEN1KMT2ABCL2L1MAPT | |
| SCHEMBL18392253 | 0.83 | MCL1 (0.77) | MCL1MEN1KMT2ABCL2L1MAPT | |
| SCHEMBL18392255 | 0.82 | MCL1 (1.00) | MCL1MEN1KMT2ABCL2L1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220396549-A1 | SMALL MOLECULE INHIBITORS OF THE MCL-1 ONCOPROTEIN AND USES THEROF | UNIV MARYLAND (US) | 2022-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220396549-A1 | SMALL MOLECULE INHIBITORS OF THE MCL-1 ONCOPROTEIN AND USES THEROF | MCL1, TP53, MYC | MCL1 1/4885MEN1 733/4885KMT2A 1516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.